Relationship between Yes-Associated Protein 1 and Prognosis of Digestive System Neoplasm: Quantitative Analysis and Bioinformatics Analysis Based on 4023 Patients

Luo Yuan Yuan; Wu Shuai; Zou Yuan-Peng; Jiang Ting; Xia Wei; He Yu-Qin

doi:10.1155/2022/3798694

Relationship between Yes-Associated Protein 1 and Prognosis of Digestive System Neoplasm: Quantitative Analysis and Bioinformatics Analysis Based on 4023 Patients

Evid Based Complement Alternat Med. 2022 Jul 19:2022:3798694. doi: 10.1155/2022/3798694. eCollection 2022.

Authors

Luo Yuan Yuan^{1

2}, Wu Shuai³, Zou Yuan-Peng⁴, Jiang Ting⁴, Xia Wei¹, He Yu-Qin¹

Affiliations

¹ Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400042, China.
² Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, China.
³ Department of Gastroenterological Surgery, Yong Chuan Hospital of Chongqing Medical University, Chongqing 400016, China.
⁴ The College of Foreign Languages and Cultures, Chongqing University, Chongqing 400030, China.

Abstract

Yes-associated protein 1 (YAP1) is involved in the development of a variety of malignancies. However, the prognosis of malignant digestive tumors with YAP1 expression is still controversial. This study searched 31 articles with 36 data sets of 4023 patients to explore the role of YAP1 expression on the prognosis of digestive malignant tumors by searching the PubMed, Embase, Web of Science, Google Scholar, and Cochrane Library databases. Specifically, relevant cancer expression matrix data were downloaded from The Cancer Genome Atlas (TCGA) database. In this meta-analysis, quantitative analysis showed that the overexpression of YAP1 was not conducive to OS (1.62, 95% CI (1.38, 1.90), P=0.001) and DFS (1.59, 95% CI (1.31, 1.93), P=0.001) in patients with digestive malignant tumors. In addition, TCGA database analysis showed that YAP1 was overexpressed in gastric cancer, cholangiocarcinoma, and colorectal cancer. Survival analysis showed that the patients with high expression of YAP1 in pancreatic cancer have a poor OS (MST: 394 vs. 691 days, P < 0.0001) and DFS (MST: 371 vs. 542 days, P=0.026) prognosis. YAP1 may be a molecular marker that effectively predicts the survival of malignant digestive tumors, especially pancreatic cancer, and is a potential therapeutic target for malignant digestive tumors.